U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07681440) titled 'A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia' on Oct. 10, 2025.
Brief Summary: The purpose of this study is to understand the patient profile, utilized treatments, treatment patterns, resulting outcomes, and associated costs relating to luspatercept treatment in patients with lower-risk myelodysplastic syndromes (LR-MDS) or beta-thalassemia in the real-world setting
Study Start Date: Nov. 16, 2023
Study Type: OBSERVATIONAL
Condition:
Myelodysplastic Syndromes
Beta-thalassemia
Intervention:
DRUG: Luspatercept
According to the product label
Recruitment St...